Bausch Health (BHC)
(Delayed Data from NYSE)
$6.36 USD
+0.01 (0.16%)
Updated May 24, 2024 04:00 PM ET
After-Market: $6.36 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Bausch Health Cos Inc. [BHC]
Reports for Purchase
Showing records 101 - 120 ( 150 total )
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Guidance Raised; Multiple Recent Advances; Raising Target to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
2Q19 Financial Results Reported; 2019 Guidance Raised; Raising Target to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Apriso Litigation Resolved; Further Debt Reduction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Recent Milestones Indicate Positive Traction; Modulating Target to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
ARVO 2019 Conference Highlights: Next-Generation Ophthalmology Therapeutics Emerge
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
DUOBRII Approval Underscores New Product Lineup Strength; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Broad Shower-to-Shower Indemnification Should Remove Minor Bear Thesis Element; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R